JP2025508676A - オミクロンコロナウイルスワクチンコンストラクトならびにこれを作製および使用する方法 - Google Patents

オミクロンコロナウイルスワクチンコンストラクトならびにこれを作製および使用する方法 Download PDF

Info

Publication number
JP2025508676A
JP2025508676A JP2024545962A JP2024545962A JP2025508676A JP 2025508676 A JP2025508676 A JP 2025508676A JP 2024545962 A JP2024545962 A JP 2024545962A JP 2024545962 A JP2024545962 A JP 2024545962A JP 2025508676 A JP2025508676 A JP 2025508676A
Authority
JP
Japan
Prior art keywords
cov
sars
chad
mice
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508676A5 (https=
JPWO2023150638A5 (https=
Inventor
ダイアモンド，マイケル
ドミトリエフ，イゴール
ハッサン，アフメド
キュリエル，デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of JP2025508676A publication Critical patent/JP2025508676A/ja
Publication of JP2025508676A5 publication Critical patent/JP2025508676A5/ja
Publication of JPWO2023150638A5 publication Critical patent/JPWO2023150638A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024545962A 2022-02-02 2023-02-02 オミクロンコロナウイルスワクチンコンストラクトならびにこれを作製および使用する方法 Pending JP2025508676A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263305979P 2022-02-02 2022-02-02
US63/305,979 2022-02-02
US202263375803P 2022-09-15 2022-09-15
US63/375,803 2022-09-15
US202263384075P 2022-11-16 2022-11-16
US63/384,075 2022-11-16
US202263434815P 2022-12-22 2022-12-22
US63/434,815 2022-12-22
PCT/US2023/061878 WO2023150638A2 (en) 2022-02-02 2023-02-02 Omicron coronavirus vaccine constructs and methods of making and using same

Publications (3)

Publication Number Publication Date
JP2025508676A true JP2025508676A (ja) 2025-04-10
JP2025508676A5 JP2025508676A5 (https=) 2026-02-10
JPWO2023150638A5 JPWO2023150638A5 (https=) 2026-02-10

Family

ID=87552962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545962A Pending JP2025508676A (ja) 2022-02-02 2023-02-02 オミクロンコロナウイルスワクチンコンストラクトならびにこれを作製および使用する方法

Country Status (7)

Country Link
EP (1) EP4473122A4 (https=)
JP (1) JP2025508676A (https=)
KR (1) KR20240137110A (https=)
CN (1) CN120282795A (https=)
AU (1) AU2023216258A1 (https=)
CA (1) CA3243465A1 (https=)
WO (1) WO2023150638A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250228929A1 (en) * 2022-04-03 2025-07-17 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
CN116987184B (zh) * 2023-09-26 2024-01-12 北京百普赛斯生物科技股份有限公司 新型冠状病毒bq.1.1突变株特异性抗体及其应用
WO2025202543A1 (en) * 2024-03-28 2025-10-02 Rokote Laboratories Finland Oy A vaccine composition comprising an adenoviral vector and an adenoviral vector delivery enhancing agent
WO2025250851A1 (en) * 2024-05-29 2025-12-04 Washington University Trivalent pan-sarbecovirus mucosal vaccine constructs and methods of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716928C (en) * 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
CA3167833A1 (en) * 2020-02-14 2021-08-19 Bertrand Victor Gilbert GEORGES Coronavirus immunogenic compositions and uses thereof
MX2022013934A (es) * 2020-05-07 2023-02-22 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle recombinante que expresa la proteina de espicula de sars-cov-2 y usos del mismo.
WO2021247567A1 (en) * 2020-06-01 2021-12-09 Washington University Coronavirus vaccine constructs and methods of making and using same

Also Published As

Publication number Publication date
EP4473122A4 (en) 2026-03-04
AU2023216258A1 (en) 2024-08-01
WO2023150638A2 (en) 2023-08-10
EP4473122A2 (en) 2024-12-11
WO2023150638A3 (en) 2023-09-14
CN120282795A (zh) 2025-07-08
CA3243465A1 (en) 2023-08-10
KR20240137110A (ko) 2024-09-19

Similar Documents

Publication Publication Date Title
US11382968B2 (en) Coronavirus immunogenic compositions and uses thereof
JP2025508676A (ja) オミクロンコロナウイルスワクチンコンストラクトならびにこれを作製および使用する方法
US20110020391A1 (en) Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu
US20210260181A1 (en) Coronavirus immunogenic compositions and uses thereof
CN116096406A (zh) 针对呼吸道合胞病毒感染的疫苗组合
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
JP2023524990A (ja) ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用
US20230227848A1 (en) Coronavirus vaccine constructs and methods of making and using same
WO2021249454A1 (en) Vaccine compositions, methods, and uses thereof
Hua et al. Enhanced humoral and CD8+ T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells
US20220275346A1 (en) Hantavirus antigenic composition
US20250049912A1 (en) Multicistronic Vaccine and Methods for Producing and Using the Same
US20240293532A1 (en) Replication-competent adenovirus type 4 sars-cov-2 vaccines and their use
US20250302896A1 (en) Vesicular stomatitis virus marburg virus vaccine
US20250152696A1 (en) Methods and compositions for vaccination against heterosubtypic influenza viruses using an adenoviral vector leading to enhanced t cell response through autophagy
WO2026055587A1 (en) Vesicular stomatitis virus marburg virus vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260202